Sign in
Taking people in United StatesPhase 1/2

Tests VT3989 alone or with other drugs in solid tumors

Tests VT3989, alone or combined, in adults with mesothelioma or advanced solid tumors.

Key facts

Who runs it
Vivace Therapeutics, Inc
Where
Arlington, Boston, Chicago, Houston, Minneapolis, New York, San Antonio, and San Francisco, United StatesSee the 9 sitesAlso in 1 other country, 3 sites
Trial code
Registry title
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
434 people, planned
Started
24 Mar 2021
Expected to end
2 Mar 2030
Type of study
Interventional, 3 groups
Treatments tested
  • VT3989
  • Nivolumab & Ipilimumab
  • Osimertinib
  • Pemetrexed/Carboplatin
Record updated
2 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mesothelioma or non-small cell lung cancer (NSCLC) with certain gene changes, in the current cohorts. The cancer must be advanced or have spread.

Age
18 years or older
Sex
All sexes can join
Disease stage
Metastatic or unresectable malignant mesothelioma (pleural or non-pleural), or incurable locally advanced or metastatic NSCLC. The disease must be measurable by scans (RECIST v1.1).
Earlier treatment
Mesothelioma cohorts: no earlier systemic therapy (cohort A) or no systemic chemotherapy (cohort C). NSCLC cohort: can join with or without earlier Osimertinib. Earlier treatment with a TEAD inhibitor is not allowed.
Biomarker or test result
NSCLC cohort: exon 19 deletions or exon 21 L858R mutations.

Main reasons for not taking part

  • Active brain metastases or primary tumors of the central nervous system
  • Known HIV positive, or active Hepatitis B or Hepatitis C
  • Pregnant or breastfeeding women
  • Significant heart disease, or QTcF interval above 470 msec
  • Another active cancer that could disturb the study results

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy
  • Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib
  • Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy
  • Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma
  • ECOG: 0-1
  • Adequate organ functions, including the liver, kidneys, and hematopoietic system

Who cannot take part

  • Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents
  • Prior treatment with TEAD inhibitor
  • History of leptomeningeal metastases
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Known HIV positive or active Hepatitis B or Hepatitis C
  • Additional active malignancy that may confound the assessment of the study endpoints
  • Corrected QT (QTcF) interval > 470 msec (using Fridericia's correction formula)
  • Active brain metastases or primary CNS (central nervous system) tumors
  • Women who are pregnant or breastfeeding

Where in United States

Also in 1 other country, 3 sites

  • Virginia Cancer Specialists, PCArlington, United StatesContact: Heather FritzTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Heather FritzTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Heather FritzTaking people
  • University of Chicago Medical CenterChicago, United StatesContact: Heather FritzTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Heather FritzTaking people
  • M Health Fairview University of Minnesota Medical CenterMinneapolis, United StatesContact: Heather FritzTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Heather FritzTaking people
  • NEXT OncologySan Antonio, United StatesContact: Heather FritzTaking people
  • UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesContact: Heather FritzTaking people

About the trial

What the trial wants to find out

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

The 3 groups in the trial

  • VT3989 Dose Escalation [Not Recruiting]Treatment being tested

    VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase

    Treatment: VT3989

  • Dose Expansion [Not Recruiting]Treatment being tested

    VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma.

    Treatment: VT3989

  • Combination [Recruiting]Treatment being tested

    For Cohort A and B, VT3989 dosed in 28 day cycles in patients with metastatic solid tumors or mesothelioma, in combination with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib). For Cohort C, VT3989 dosed in 21 day cycles in patients with mesothelioma in combination with chemotherapy (pemetrexed+carboplatin) for 4-6 cycles, then continuing VT3989 as monotherapy on 28-day cycle.

    Treatment: VT3989, Nivolumab & Ipilimumab, Osimertinib, and Pemetrexed/Carboplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
Plain-language title
Tests VT3989 alone or with other drugs in solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
2 April 2026